In HER2-positive breast cancer patients, LVEF was significantly decreased 2 weeks after completion of doxorubicin treatment (Fig. 2A), while the E/e’ ratio and LF/HF ratio were unchanged (Fig. 2B, C). The gene discussed is ERBB2; the disease is breast cancer.